Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia
() -- Curis (CRIS) said Monday it has consented the first six patients in a phase 2 study of emavusertib in chronic lymphocytic leukemia, or CLL, just days after opening 11 clinical sites for enrollment. The biotechnology company said it continues to expect to dose the first five trial participants by the end of July a